Hu Tingting, Dong Yinmiao, Yang Chenghao, Zhao Mingyi, He Qingnan
Department of Pediatrics, The Third Xiangya Hospital, Central South University, Changsha, China.
Front Physiol. 2021 Oct 14;12:749544. doi: 10.3389/fphys.2021.749544. eCollection 2021.
Allergic diseases comprise a genetically heterogeneous cluster of immunologically mediated diseases, including asthma, food allergy (FA), allergic rhinitis (AR) and eczema, that have become major worldwide health problems. Over the past few decades, the spread of allergic diseases has displayed an increasing trend, and it has been reported that 22% of 1.39 billion people in 30 countries have a type of allergic disease. Undoubtedly, allergic diseases, which can be chronic, with significant morbidity, mortality and dynamic progression, impose major economic burdens on society and families; thus, exploring the cause of allergic diseases and reducing their prevalence is a top priority. Recently, it has been reported that the gastrointestinal (GI) microbiota can provide vital signals for the development, function, and regulation of the immune system, and the above-mentioned contributions make the GI microbiota a key player in allergic diseases. Notably, the GI microbiota is highly influenced by the mode of delivery, infant diet, environment, antibiotic use and so on. Specifically, changes in the environment can result in the dysbiosis of the GI microbiota. The proper function of the GI microbiota depends on a stable cellular composition which in the case of the human microbiota consists mainly of bacteria. Large shifts in the ratio between these phyla or the expansion of new bacterial groups lead to a disease-promoting imbalance, which is often referred to as dysbiosis. And the dysbiosis can lead to alterations of the composition of the microbiota and subsequent changes in metabolism. Further, the GI microbiota can affect the physiological characteristics of the human host and modulate the immune response of the host. The objectives of this review are to evaluate the development of the GI microbiota, the main drivers of the colonization of the GI tract, and the potential role of the GI microbiota in allergic diseases and provide a theoretical basis as well as molecular strategies for clinical practice.
过敏性疾病是一组由免疫介导的、具有遗传异质性的疾病,包括哮喘、食物过敏(FA)、过敏性鼻炎(AR)和湿疹,已成为全球主要的健康问题。在过去几十年中,过敏性疾病的传播呈上升趋势,据报道,30个国家的13.9亿人口中有22%患有一种过敏性疾病。毫无疑问,过敏性疾病可能是慢性的,具有较高的发病率、死亡率和动态进展,给社会和家庭带来了重大经济负担;因此,探索过敏性疾病的病因并降低其患病率是当务之急。最近,有报道称胃肠道(GI)微生物群可以为免疫系统的发育、功能和调节提供重要信号,上述作用使GI微生物群成为过敏性疾病的关键因素。值得注意的是,GI微生物群受到分娩方式、婴儿饮食、环境、抗生素使用等因素的高度影响。具体而言,环境变化可导致GI微生物群失调。GI微生物群的正常功能依赖于稳定的细胞组成,就人类微生物群而言,主要由细菌组成。这些门之间比例的大幅变化或新细菌群体的扩张会导致促病失衡,这通常被称为失调。而失调会导致微生物群组成的改变以及随后的代谢变化。此外,GI微生物群可影响人类宿主的生理特征并调节宿主的免疫反应。本综述的目的是评估GI微生物群的发育、胃肠道定植的主要驱动因素以及GI微生物群在过敏性疾病中的潜在作用,并为临床实践提供理论基础和分子策略。